Publication

Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021

Journal Paper/Review - Mar 12, 2021

Units
PubMed
Doi

Citation
Fankhauser C, Tandstad T, Nicolai N, Nicol D, Leão R, Muilwijk T, Janisch F, Mayor de Castro J, Gremmels H, Fizazi K, Fischer S, Boormans J, Bokemeyer C, Algaba F, Albers P, Oldenburg J, Pilar Laguna M. Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. Eur Urol 2021; 80:4-6.
Type
Journal Paper/Review (English)
Journal
Eur Urol 2021; 80
Publication Date
Mar 12, 2021
Issn Electronic
1873-7560
Pages
4-6
Brief description/objective

Men with metastatic germ cell tumors undergoing chemotherapy are at high risk of venous thromboembolic events and low risk of bleeding. A central venous-access device should be avoided whenever possible. Thromboprophylaxis may be prescribed after balancing the risks and benefits for each individual patient.